Re: Zenith and Breast Cancer

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

masila

Rank: Vice President [?]

Points: 818 [?]

Votes: 16 Score: 3.7 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith and Breast Cancer

in response to

Re: Zenith and Breast Cancer

BearDownAZ

posted on Mar 11, 2018 02:36PM

I recall hearing about 3309 back in 2014 . I did find the following:

A lead candidate, ZEN 3309, is being developed as a next generation pan-selective BET bromo-domain inhibitor, for the treatment of cancer and autoimmune disorders. ZEN 3309 is a BRD4 protein inhibitor targeting several mechanisms of resistance to endocrine therapies in preclinical models of ER+ breast cancers.

Also mentioned in a presentation at EpiCongress 2014, so it's been in the stable for a while.

https://www.zenithepigenetics.com/upload/media_element/16/01/zenith-epigenetics-presentation---epicongress-boston-july-2014.pdf